Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 8901 results

  1. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  2. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  19 August 2026

    Highly specialised technologies guidance
    In development

  3. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date: TBC

    NICE guideline
    In development

  4. Polycystic ovary syndrome: assessment and management

    In development Reference number: GID-NG10436 Expected publication date:  03 November 2026

    NICE guideline
    In development

  5. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  6. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  8. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  9. Pharmalgen for the treatment of bee and wasp venom allergy

    In development Reference number: GID-TA11898 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]

    In development Reference number: GID-TA11625 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  13. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

    NICE guideline
    In consultation

  15. Prognostic tests for multiple myeloma

    Awaiting development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    Awaiting development